Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Puja Sapra

Showing results (51-60 of 56) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 56 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 31, 2020
A Novel GUCY2C-CD3 T-Cell Engaging Bispecific Construct (PF-07062119) for the Treatment of Gastrointestinal CancersDivya Mathur, Adam R Root, Bozena Bugaj-Gaweda, et al.
Science Translational Medicine|January 13, 2017
A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressionsMarc Damelin, Alexander Bankovich, Jeffrey Bernstein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2022
Design and Preclinical Evaluation of a Novel B7-H4-Directed Antibody-Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305Krista Kinneer, Philipp Wortmann, Zachary A Cooper, et al.
Molecular Cancer Therapeutics|May 14, 2025
A Novel B7-H4xCD3 Bispecific T Cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune-Checkpoint TherapiesKeith Abayasiriwardana, Lei Wu, Hanane Laklai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2025
Derivation of AZD5335, a Novel FRα-Targeted TOP1i-Loaded ADC, for the Treatment of FRα-Expressing CancersJason J Zoeller, Ravinder Tammali, Roger B Dodd, et al.
Mabs|January 18, 2021
Discovery and optimization of a novel anti-GUCY2c x CD3 bispecific antibody for the treatment of solid tumorsAdam R Root, Gurkan Guntas, Madan Katragadda, et al.
Pageof 6

Showing results (51-60 of 56) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 56 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 31, 2020
A Novel GUCY2C-CD3 T-Cell Engaging Bispecific Construct (PF-07062119) for the Treatment of Gastrointestinal CancersDivya Mathur, Adam R Root, Bozena Bugaj-Gaweda, et al.
Science Translational Medicine|January 13, 2017
A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressionsMarc Damelin, Alexander Bankovich, Jeffrey Bernstein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2022
Design and Preclinical Evaluation of a Novel B7-H4-Directed Antibody-Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305Krista Kinneer, Philipp Wortmann, Zachary A Cooper, et al.
Molecular Cancer Therapeutics|May 14, 2025
A Novel B7-H4xCD3 Bispecific T Cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune-Checkpoint TherapiesKeith Abayasiriwardana, Lei Wu, Hanane Laklai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2025
Derivation of AZD5335, a Novel FRα-Targeted TOP1i-Loaded ADC, for the Treatment of FRα-Expressing CancersJason J Zoeller, Ravinder Tammali, Roger B Dodd, et al.
Mabs|January 18, 2021
Discovery and optimization of a novel anti-GUCY2c x CD3 bispecific antibody for the treatment of solid tumorsAdam R Root, Gurkan Guntas, Madan Katragadda, et al.
Pageof 6